Comparative safety and efficacy of bisphosphonates, denosumab, and parathyroid hormone analogs for osteoporosis following lung transplantation
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2025
DOI: 10.1002/phar.70040 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2025. Verfasst von Spenser E January und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Barnes-Jewish Hospital, Saint Louis, Missouri, USA. Hauptthemen laut MEDLINE: Lung Transplantation, Denosumab, Bone Density Conservation Agents, Osteoporosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Abstract (Originalsprache)
Background
Parathyroid hormone (PTH) analogs, denosumab, and bisphosphonates are used to treat osteoporosis but have been associated with infections in the general population. Osteoporosis is a common comorbidity following lung transplantation. However, infections increase the risk of developing chronic lung allograft dysfunction, which reduces survival. Evidence for safe and effective use of PTH analogs, denosumab, or bisphosphonates in lung transplant recipients is lacking.
Methods
This single‐center retrospective study evaluated lung transplant patients treated with the PTH analogs teriparatide or abaloparatide, RANKL inhibitor denosumab, or bisphosphonates. The primary outcome of interest was the incidence of infection while on the osteoporosis medication, and a multivariable logistic regression was employed to control for infection confounders. Secondary endpoints were treated allograft rejection episodes, the incidence of new donor‐specific antibodies, the incidence of fracture while on medication, and the change in bone mineral density (BMD) from the start to the end of osteoporosis medication use.
Results
Forty‐four PTH analog courses and 48 denosumab courses were compared with 92 bisphosphonate courses. Infection incidence was significantly lower in the PTH analog group than the denosumab or bisphosphonate group, but this did not retain significance on multivariable modeling. Treated allograft rejection episodes were higher in those with bisphosphonate use, significantly so when compared to PTH analog patients, but patients treated with bisphosphonates were also started on therapy earlier after their transplant when rejection risk is higher. All agents were effective at increasing BMD of the lumbar spine, none improved BMD of the femoral neck, and only PTH analogs significantly improved hip BMD.
Conclusion
In this retrospective study of lung transplant patients treated for osteoporosis post‐transplant, there was no difference in risk of infections in patients treated with PTH analogs, denosumab, or bisphosphonate therapies when examined with multivariable modeling. PTH analogs were the most effective since they significantly improved BMD at both the hip and lumbar spine, whereas denosumab and bisphosphonates only improved lumbar spine BMD. This study supports that PTH analogs and denosumab, despite their association with infection in the general population, may be safely utilized compared to bisphosphonates in the post‐lung transplant population for the treatment of osteoporosis, but larger studies are needed to confirm these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Barnes-Jewish Hospital, Saint Louis, Missouri, USA.
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, Washington University School of Medicine, Saint Louis, Missouri, USA.
ORCID-Profile: Spenser E January, Keith A Fester, Jesus E Escamilla, Marlene Cano
Zitieren
APA
January, S. E., Fester, K. A., Escamilla, J. E., & Cano, M. (2025). Comparative safety and efficacy of bisphosphonates, denosumab, and parathyroid hormone analogs for osteoporosis following lung transplantation. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.70040
Vancouver
January SE, Fester KA, Escamilla JE, Cano M. Comparative safety and efficacy of bisphosphonates, denosumab, and parathyroid hormone analogs for osteoporosis following lung transplantation. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2025. doi:10.1002/phar.70040
BibTeX
@article{January2025,
author = {January, Spenser E and Fester, Keith A and Escamilla, Jesus E and Cano, Marlene},
title = {Comparative safety and efficacy of bisphosphonates, denosumab, and parathyroid hormone analogs for osteoporosis following lung transplantation},
journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
year = {2025},
doi = {10.1002/phar.70040}
}
EUVIMED